Stem cell replacement has emerged as the novel therapeutic strategy for Parkinson's
disease (PD). Control of motor behavior is lost in PD due to the selective degeneration of …

The aim of stem cell therapy for Parkinson's disease is to reconstruct nigro–striatal neuronal
pathways using endogenous neural stem/precursor cells or grafted dopaminergic neurons …

Parkinson's disease (PD) is the second most common neurodegenerative disorder after
Alzheimer's disease, affecting 1%–2% of the population over the age of 65. As the …

The concept of cell replacement to compensate for cell loss and restore functionality has
entered several disease entities including neurodegenerative disorders. Recent clinical …

A major neuropathological feature of Parkinson's disease (PD) is the loss of nigrostriatal
dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and …

Motor dysfunctions in Parkinson's disease are considered to be primarily due to the
degeneration of dopaminergic neurons in the substantia nigra pars compacta …

Early clinical trials designed to treat Parkinson's disease by transplantation of fetal tissue
containing dopamine neuron precursors yielded promising results, but the approach retains …

✓ In this review, the authors discuss recent advances in the field of cell therapy for Parkinson
disease (PD). They compare and contrast recent clinical trials using fetal dopaminergic …

Motor djsfunctions in Parkinson's disease a· e believed to be primarily due to the
degeneration of dopamincrgic neurons located in the substantia nigra pars compacta …

Current therapeutic approaches for Parkinson's disease (PD) provide symptomatic relief but
none of them change the course of disease. There is therefore a clear need for regenerative …